Sun-Novo: The first-instance judgment of the lawsuit requires Hang Seng Pharmaceutical to pay 2.4032 million yuan

Zhitong
2025.11.03 08:40

Sun-Novo announced that, as the defendant and counterclaimant, the first-instance judgment of the lawsuit requires Hang Seng Pharmaceutical to pay the company a total of RMB 4.4032 million for research and development expenses and remuneration, while the company is to compensate Hang Seng Pharmaceutical RMB 2 million. After offsetting, Hang Seng Pharmaceutical still needs to pay RMB 2.4032 million. The total case acceptance fee for both the main lawsuit and the counterclaim is RMB 122,500, of which Hang Seng Pharmaceutical bears RMB 74,500 and the company bears RMB 48,000. Since the company has fully provided for bad debt reserves for the relevant accounts receivable, this lawsuit has no negative impact on the current and future profits. The case is currently in the appeal period, and the final impact will be subject to the actual execution situation

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.